10.1016/j.neuint.2010.01.006 [DOI] [PubMed] [Google Scholar] 53.Held KD, Epp ER, Awad S, Biaglow JE
Recent surveillance using positron emission tomography revealed no distant metastasis
As a dual GIP/GLP-1 receptor agonist, it has demonstrated superior effectiveness in both clinical trials and real-world studies
En octubre del 2025 la FDA amplio la indicacin de simaglutida para la reduccin del riesgo de eventos cardiovasculares mayores (muerte cardiovular, infarto al miocardio no fatal, ataque vascular no fatal) en adultos con diabetes mellitus tipo 2 (no insulinodependiente) que tienen riesgo alto de desarrollar estos eventos
Ad commonly reported gastrointestinal side effects nausea, vomiting, diarrhea, and gastric discomfort and the result is at odds with the demands of endurance training, which sets the stage for low-energy availability, dehydration, impaired recovery, and RED-S